Goldman Sachs Reiterates Buy Rating on Stoke Therapeutics (STOK) Post Investor Meeting

September 10, 2026 4:57 AM

Goldman Sachs analyst Kevin Strang reiterated a Buy rating and $44.00 price target on Stoke Therapeutics (NASDAQ: STOK).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found